A recent Wall Street Journal (WSJ) article outlines the unusual and extraordinary steps one of CICP’s board member companies Eli Lilly and Co. had to take to develop a new antibody-based drug for COVID-19 that has now been approved by the U.S. Food and Drug Administration (FDA) for emergency use.
The article states “What Lilly has gone through to get to this point reflects not only the common challenges all businesses face in the pandemic, but also unique ones that push drugmakers to the limit of their ability to operate.”
The WSJ article has been republished and can be found HERE.
